Pharma Mar (OTCMKTS:PHMMF) Short Interest Update

Pharma Mar (OTCMKTS:PHMMF) was the target of a significant increase in short interest in the month of August. As of August 31st, there was short interest totaling 8,682 shares, an increase of 9,136.2% from the August 15th total of 94 shares. Based on an average daily trading volume, of 36 shares, the short-interest ratio is currently 241.2 days. Approximately 0.0% of the company’s shares are short sold.

Pharma Mar Price Performance

PHMMF stock opened at $94.60 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.02 and a quick ratio of 2.44. Pharma Mar has a 1 year low of $77.41 and a 1 year high of $110.40. The firm has a 50-day moving average of $88.98 and a 200 day moving average of $93.95.

Wall Street Analyst Weigh In

Several research analysts have recently commented on PHMMF shares. Chardan Capital upgraded Pharma Mar to a “strong-buy” rating in a report on Tuesday, June 9th. Zacks Research raised Pharma Mar to a “hold” rating in a research note on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy”.

Pharma Mar Company Profile

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.